Related Experiment Video

Updated: Aug 30, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer

Jin T E Lim1, Gary A Piazza, Rifat Pamukcu

  • 1Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York 10021, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 29, 2003
PubMed

Insights

Sulindac sulfide and related compounds inhibit prostate cancer cell growth by targeting the androgen receptor (AR) signaling pathway. This mechanism reduces prostate-specific antigen (PSA) levels, offering a novel therapeutic approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer cell lines exhibit growth inhibition and apoptosis when treated with sulindac sulfide (SS), exisulind, CP248, and CP461.
  • These effects are independent of cyclooxygenase expression, p53 mutations, or bcl-2 overexpression.
  • Exisulind demonstrated efficacy in inhibiting the growth of androgen-dependent LNCaP human prostate cancer xenografts in nude mice.

Purpose of the Study:

  • To investigate the impact of SS, exisulind, CP248, and CP461 on prostate-specific antigen (PSA) secretion and cellular levels.
  • To elucidate the role of the androgen receptor (AR) signaling pathway in mediating the effects of these compounds.
  • To compare the efficacy of SS and exisulind against CP248 and CP461 in inhibiting AR signaling and PSA expression.

Main Methods:

  • Treatment of human prostate cancer cell lines and LNCaP xenografts with SS, exisulind, CP248, and CP461.
  • Measurement of PSA secretion and cellular levels.
  • Assessment of AR protein and mRNA levels.
  • Transient transfection assays to evaluate AR promoter activity using a luciferase reporter.

Main Results:

  • Compounds induced decreased PSA secretion and cellular PSA levels in LNCaP cells.
  • Treated cells showed reduced AR protein and mRNA levels, indicating AR signaling pathway inhibition.
  • SS and exisulind were more potent in inhibiting PSA and AR expression compared to CP248 and CP461.
  • Differential effects on transcription factors may explain the varying efficacy of the compounds.

Conclusions:

  • Growth inhibition and apoptosis in prostate cancer cells by these compounds are partly mediated by AR signaling pathway inhibition.
  • These compounds represent a potential novel strategy for prostate cancer prevention and treatment.
  • Targeting AR signaling offers a promising avenue for therapeutic intervention in prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Internal Receptors01:56

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.